Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

What To Look Out For At ESMO 2025

Oct 10 2025

• By Alexandra Shimmings and Kevin Grogan

Scene of Berlin — (Shutterstock)

Related Content

AstraZeneca And Daiichi Sankyo’s Datroway Scores Survival Success In TNBC

Oct 06 2025

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

May 07 2025

ASCO: Trodelvy First-Line TNBC Data Seen As Potentially Practice-Changing

May 31 2025

‘Attenuated’ Survival Benefit In Bemarituzumab Trial Delays Filing Plans

Sep 04 2025

Then There Were Two: Lilly Gets FDA Nod For Oral SERD

Sep 26 2025

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

Sep 22 2025

Data From China Bolster Summit/Akeso’s Case For Ivonescimab

Apr 23 2025

Summit Fails To Reassure On Ivonescimab’s US Approvability

Sep 08 2025

Related Companies

AstraZeneca PLC

Daiichi Sankyo Co., Ltd.

Merck & Co., Inc.

Gilead Sciences, Inc.

Pfizer Inc.

Astellas Pharma, Inc.

Novartis AG

Roche Holding AG

Celcuity, Inc.

Amgen, Inc.

Zai Lab Ltd.

Immatics N.V.

Summit Therapeutics Inc.

Akeso Inc.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

RemeGen Ltd.

More from ESMO

More from Conferences

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window